Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer.

Cancer Res Commun · 2026 · PMC13276731 · PMID 42127914

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

16%, Wilcoxon P = 0.2) and baseline BRAF V600 VAF (3.53% and 15.85%, Wilcoxon P = 0.070) between BRAFi-naive and BRAFi-experienced patients show a notable trend that may reflect the more aggressive biology or higher disease burden typically seen in patients who have progressed on prior lines of therapy.

also in 2,105 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.